The Manufacturers Life Insurance Company Acquires 18,774 Shares of Hologic, Inc. (NASDAQ:HOLX)

The Manufacturers Life Insurance Company lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,554,032 shares of the medical equipment provider's stock after buying an additional 18,774 shares during the period. The Manufacturers Life Insurance Company owned approximately 1.10% of Hologic worth $208,051,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HOLX. Swedbank AB purchased a new position in shares of Hologic in the 1st quarter worth $120,827,000. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares during the period. Mackenzie Financial Corp grew its stake in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock valued at $66,506,000 after purchasing an additional 815,960 shares during the period. Marshall Wace LLP purchased a new stake in shares of Hologic during the 2nd quarter valued at about $39,427,000. Finally, Hsbc Holdings PLC lifted its stake in shares of Hologic by 14.6% in the 2nd quarter. Hsbc Holdings PLC now owns 2,034,651 shares of the medical equipment provider's stock worth $151,100,000 after purchasing an additional 259,185 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HOLX has been the topic of several analyst reports. Citigroup cut shares of Hologic from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their price target on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Stephens reaffirmed an "overweight" rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Leerink Partners cut their price objective on Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Finally, Raymond James increased their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and a consensus target price of $89.91.

Hologic Price Performance

HOLX traded up $0.28 during trading on Wednesday, hitting $79.28. 250,224 shares of the company traded hands, compared to its average volume of 1,588,871. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $18.41 billion, a PE ratio of 23.72, a P/E/G ratio of 2.51 and a beta of 0.98. The stock's 50-day simple moving average is $80.38 and its two-hundred day simple moving average is $78.38. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the business posted $0.89 earnings per share. The business's quarterly revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.